Bristol-Myers Squibb Company
GSK-3 inhibitors
Last updated:
Abstract:
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
27 Nov 2017
Issue date:
25 Aug 2020